Eli Lilly's Mounjaro ( tirzepatide ) is now FDA-approved to reduce cardiovascular risk in adults with type 2 diabetes (T2D).
Marilynn Larkin is a medical journalist and editor at Medscape. With over 25 years of experience, she specializes in health and wellness, covering topics such as endocrinology, nutrition, fitness, and mental health, while also exploring healthcare technology and alternative medicine. Marilynn's work has been featured in prominent outlets including Environmental Health News, Yahoo News, and WebMD.